HCA Healthcare price target raised to $430 from $390 at Truist

Truist analyst David MacDonald raised the firm’s price target on HCA Healthcare to $430 from $390 and keeps a Buy rating on the shares. Truist remains bullish on HCA following an upbeat management call that highlighted the robust demand environment which is helping drive broad-based, balanced growth across segments, continued efficiency gains on a handful of fronts aided by targeted initiatives, and ongoing labor improvement, the analyst tells investors in a research note. The firm continues to view HCA’s collection of assets in attractive markets as well positioned and expects “superb” financial flexibility to support ongoing growth investment, capacity and service line expansion complemented by shareholder value creation.